1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Vista Gold entered into an Arrangement Agreement on September 20, 2026, under which Artemis Gold would acquire all of Vista's common shares through a court-approved plan of arrangement. Vista shareholders would receive 0.0966 Artemis Gold shares for each Vista share, which the companies say implies US$2.83 per share and a 29% premium to Vista's 20-day volume-weighted average price. The deal requires Vista shareholder approval and other regulatory and court approvals, and the companies expect completion in January 2027.
Exchange ratio of 0.0966 Artemis Gold common shares per Vista Gold share, implying US$2.83 per share and a total transaction value of about US$427 million on a 100% basis
Premium of 29% to the 20-day VWAP as of September 18, 2026, and 25% to the last closing price, according to the companies
Vista must pay a termination fee of US$18,148,536 in certain circumstances, and either party may terminate if the Effective Time has not occurred by April 15, 2027
Directors and officers have signed voting support agreements, and Vista expects its proxy statement to be mailed in November 2026 with a shareholder meeting in December 2026
On September 21, 2026, Insulet entered into a Ninth Amendment to its Credit Agreement with Morgan Stanley Senior Funding as administrative agent. The $475 million of existing term loans were replaced with new term loans at a margin 0.25% lower, and revolving commitments rose by $250 million to $750 million, which were undrawn at closing. For shareholders, the filing points to lower borrowing costs and more available credit, though it does not state a dollar effect on earnings.
New term loans of $475 million replaced existing term loans of equal amount, issued at par.
Term SOFR loan margin on new term loans is 1.75%, 0.25% lower than the existing margin, with a 0.00% SOFR floor.
Revolving credit commitments increased by $250 million to $750 million, undrawn at closing; term SOFR margin range cut to 1.25% to 1.75%.
The European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based treatments for primary hypercholesterolaemia or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide. The company's partner Menarini holds European commercialization rights, and the approvals trigger milestone payments in the mid-teens of millions of euros, with up to an additional €833 million available on future milestones.
Approvals cover all EU Member States, Iceland, Liechtenstein and Norway
Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe
EC requires a post-authorization efficacy study and final results from the PREVAIL cardiovascular outcomes trial
Menarini milestone payments in the mid-teens of millions of euros triggered by the authorizations
Trilogy Metals said the U.S. Army Corps of Engineers has published a Notice of Intent to prepare an Environmental Impact Statement for its flagship Arctic Project in northwestern Alaska, formally starting the National Environmental Policy Act review and a public scoping phase. The company said the schedule still targets a draft EIS in October 2027 and a Record of Decision in September 2028, which shareholders may watch as the project's main federal permitting milestones.
Notice of Intent published by the U.S. Army Corps of Engineers, announced September 21, 2026, launching public scoping
Schedule continues to target a draft EIS in October 2027 and a Record of Decision in September 2028
Clean Water Act Section 404 permit application was filed by Ambler Metals on April 20, 2026
Arctic Project is advanced by Ambler Metals LLC, a 50/50 joint venture with South32
Richtech Robotics received a statement of work under its existing master services agreement with a national retailer on September 18, 2026. The client agreed to buy and deploy 200 DUST-E autonomous cleaning robots over five years, plus ongoing ancillary services such as automated reporting and remote support. The filing gives no contract value, so its financial size relative to the company is not disclosed.
Client agreed to purchase and deploy 200 DUST-E autonomous cleaning robots over a five-year period
Statement of work received September 18, 2026 under the master services agreement first reported August 25, 2025
Scope also includes ongoing ancillary services such as automated reporting and remote support
Cue Biopharma announced positive topline results from a Phase 2 trial of CUE-221 in chronic spontaneous urticaria (CSU), conducted in China by Genesis Life Sciences with 145 participants. The primary endpoint was met at all dose levels, and the company plans a Phase 2b/3 CSU trial and a Phase 2 food allergy trial, subject to FDA review of the Phase 2 data. The filing contains clinical data only, with no revenue, earnings, cash or financing figures.
Primary endpoint (complete resolution of hives, HSS7=0, at week 12): 54% at 4 mg/kg, 53% at 2 mg/kg and 43% at 1 mg/kg, vs. 11% for placebo and 41% for omalizumab 300 mg.
Key secondary endpoint (UAS7=0 at week 12) was statistically significant at 4 mg/kg: 46% vs. 11% for placebo.
At week 28, 12 weeks off drug, complete resolution of hives was 60% at 4 mg/kg vs. 24% for omalizumab, a 36% difference (post hoc analysis).
No treatment-related serious adverse events and no hypersensitivity reactions, including anaphylaxis, were reported; the company will present full data at an upcoming scientific meeting.
Priority Technology Holdings signed a merger agreement on September 18, 2026, with an investor group led by Chairman and CEO Thomas Priore. The group will acquire the shares it does not already own for $8.05 per share in cash, an enterprise value of approximately $1.6 billion. Shareholders receive cash but would stop holding shares in a publicly listed company once the deal closes, which is expected in the first half of 2027.
Merger agreement dated September 18, 2026; $8.05 per share in cash; enterprise value of approximately $1.6 billion
The price is a 38% premium to the September 18, 2026 close and a 65% premium to the November 7, 2025 unaffected price
Approval requires a majority of shares not affiliated with the investor group; the company must pay a $15,750,000 termination fee in certain cases
Expected to close in the first half of 2027; common stock will no longer be listed on the Nasdaq Global Select Market
WESCO's subsidiary Wesco Distribution amended its ABL revolving credit facility and its receivables securitization facility on September 17, 2026. The amendments extend both facilities, raise the commitments and purchase limits, and lower interest and drawn spreads, giving the company more borrowing capacity on longer terms.
ABL Facility commitments rise from $1,725 million to $1,850 million, with maturity extended to September 17, 2031.
Receivables Facility purchase limit rises from $1,550 million to $1,750 million, with termination date extended to September 17, 2029.
Interest rate spreads on the ABL Facility and drawn spreads on the Receivables Facility decrease under the amendments.
Barclays Bank PLC is administrative agent for the ABL Facility; PNC Bank, National Association is administrator for the Receivables Facility.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.